No Association Found Between Opioid Use, Breast Cancer Recurrence
the Cancer Therapy Advisor take:
No clinical evidence was found to support a relationship between opioid prescriptions used to manage pain and risk of breast cancer recurrence, according to an article published online in the journal Cancer.
A total of 34,188 patients with incident, early stage breast cancer diagnosed between 1996 and 2008 in Denmark were identified from the Danish Breast Cancer Cooperative Group Registry. Data regarding opioid prescriptions were gathered from the Danish National Prescription Registry.
Results showed no correlation between ever-use of opioids (regardless of opioid type, strength, chronicity of use, or cumulative dose) and breast cancer recurrence (crude hazard ratio [HR], 0.98; 95% CI: 0.90, 1.1; adjusted HR, 1.0; 95% CI: 0.92, 1.1).
Furthermore, breast cancer recurrence rates were reduced among patients who used strongly (but not weakly) immunosuppressive opioids. The authors noted this could have possibly been due to channeling bias among those with a high competing risk.
The study argued the findings were important for patients with cancer given that opioids are commonly used to manage pain related to comorbid conditions.
No clinical evidence found to support a relationship between opioid prescriptions used to manage pain and risk of breast cancer recurrence.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
- Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
- Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models